Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis

MedImmune

Status and phase

Completed

Phase 2

Conditions

Psoriasis

Treatments

Drug: MEDI-507

Study type

Interventional

Funder types

Industry

Identifiers

NCT00192452

MI-CP074

Details and patient eligibility

About

The primary objective of this study is to compare disease activity, as measured by PASI score, of two MEDI-507 dose levels (0.012 and 0.04 mg/kg) versus placebo administered by intravenous infusion every 2 weeks for a total of 8 infusions.

Sex

All

Ages

18 to 64 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Plaque psoriasis involving at least 10% of body surface area (Appendix B)
Age 18 through 65 years at the time of the first dose of study drug
Both males and females are eligible. However, sexually active females, unless surgically sterile or at least 1 year post-menopausal, must have used an effective method of avoiding pregnancy (including oral or implanted contraceptives, IUD, female condom, diaphragm with spermicide, cervical cap, abstinence, use of a condom by the sexual partner or sterile sexual partner) for 30 days prior to the first dose of study drug and must agree to continue using such precautions for 60 days after the final dose of study drug
Currently receiving no therapy for psoriasis except emollients (certain other over-the-counter products may be allowed with prior approval of the sponsor)
Written informed consent obtained from the patient
Ability to complete follow-up period of 188 days as required by the protocol

Exclusion criteria

Pustular, guttate, or erythrodermic psoriasis as the predominant disease type
PASI score <8
At screening (must be within 21 days before study entry) any of the following: lymphocyte count under 1,200 cells/mm3, WBC under 4,000 cells/mm3, hematocrit below 32%, platelets below 110,000 cells/mm3, creatinine, AST, ALT over 1.5 times upper limit of normal
At screening (must be within 21 days before study entry) any clinical evidence of HIV, hepatitis B, hepatitis C or active hepatitis A infection
Pregnancy (must have a negative serum pregnancy test within 21 days prior to the first dose of study drug, and urine pregnancy test must be negative on Study Day 0 before study entry)
History of cancer (except excision of basal cell carcinoma)
Any documented immunodeficiency
A history of prior administration of monoclonal antibodies or related proteins, with the exception of MEDI-507 (Note: prior recipients of MEDI-507 will require review and approval by the sponsor prior to entry)
Receipt of systemic retinoids, corticosteroids, cyclosporin A, methotrexate, phototherapy or coal tar treatment in the past 4 weeks
Use of topical therapy (except emollients) for psoriasis in the past 2 weeks (certain other over-the-counter products may be allowed with prior approval of the sponsor)
Receipt of any investigational drug therapy within 6 weeks before the first dose of study drug in this protocol (use of licensed agents for indications not listed in the package insert is permitted)
Current or planned participation in a research protocol in which an investigational agent or therapy may be administered
Nursing mother
Acute illness including infections
Clinical manifestations of significant end organ dysfunction or failure that may compromise the safety of the volunteer in the study
A known drug allergy or medical contraindication to ibuprofen